Cargando…

Silencing human epidermal growth factor receptor‐3 radiosensitizes human luminal A breast cancer cells

Endocrine therapy and radiotherapy are the main treatments for luminal A breast cancer. However, drug and radiotherapy resistance could occur during long‐term treatment, leading to local recurrence and distant metastasis. Some studies have found that drug resistance might be related to human epiderm...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Guofeng, Di, Xiaoke, Yan, Jingjing, Zhu, Caiqiang, Sun, Xinchen, Zhang, Shu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272105/ https://www.ncbi.nlm.nih.gov/pubmed/30259607 http://dx.doi.org/10.1111/cas.13810

Ejemplares similares

The curative effects of radiotherapy-based therapies for human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis
por: Shao, Minghai, et al.
Publicado: (2017)

Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
por: Yu, Tosol, et al.
Publicado: (2016)

Overrepresentation of human epidermal growth factor receptor 2 positive- and Luminal B breast cancer metastases in the eyes and orbit
por: Stålhammar, Gustav, et al.
Publicado: (2022)

Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells
por: Li, Ping, et al.
Publicado: (2013)

Radiosensitization of head and neck cancer by targeting the epidermal growth factor receptor
por: Goel, Arun Kumar, et al.
Publicado: (2009)

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization
por: Gee, Julia MW, et al.
Publicado: (2003)

Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings
por: Hashmi, Atif A, et al.
Publicado: (2023)

Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy
por: Griffith, James, et al.
Publicado: (2017)

Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells
por: Tien, Yun, et al.
Publicado: (2020)

Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
por: Yue, Li, et al.
Publicado: (2020)

Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes
por: Vrba, Lukas, et al.
Publicado: (2017)

Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
por: Hagen, Katie R, et al.
Publicado: (2013)

Epidermal growth factor receptor function in the human urothelium
por: Wasén, C., et al.
Publicado: (2018)

Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review
por: Zhang, Xiao, et al.
Publicado: (2014)

Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.
por: Sharma, A. K., et al.
Publicado: (1994)

Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022)

Validation of the Prognostic Stage from the American Joint Committee on Cancer 8th Staging Manual in Luminal B-Like Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Ding, Jinhua, et al.
Publicado: (2022)

Src-Mediated Cross-Talk between Farnesoid X and Epidermal Growth Factor Receptors Inhibits Human Intestinal Cell Proliferation and Tumorigenesis
por: Peng, Zhongsheng, et al.
Publicado: (2012)

Epidermal Growth Factor Receptor Silencing Blunts the Slow Force Response to Myocardial Stretch
por: Brea, María S., et al.
Publicado: (2016)

Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells
por: Wen, Yuqing, et al.
Publicado: (2019)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells
por: Pan, Shawn, et al.
Publicado: (2015)

Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Lee, Changro, et al.
Publicado: (2016)

FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
por: Chung, Wei-Pang, et al.
Publicado: (2022)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Epidermal growth factor receptors (EGFR) in human ovarian cancer.
por: Owens, O. J., et al.
Publicado: (1991)

Silencing NFBD1/MDC1 enhances the radiosensitivity of human nasopharyngeal cancer CNE1 cells and results in tumor growth inhibition
por: Wang, Z, et al.
Publicado: (2015)

Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan
por: Almasri, Nidal M, et al.
Publicado: (2005)

Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2
por: Li, Jiayu, et al.
Publicado: (2021)

Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report
por: Yu, Jing, et al.
Publicado: (2022)

Siah1 proteins enhance radiosensitivity of human breast cancer cells
por: He, Hai-Tao, et al.
Publicado: (2010)

Rad51 in regulating the radiosensitivity of non‐small cell lung cancer with different epidermal growth factor receptor mutation status
por: Zhong, Xing, et al.
Publicado: (2015)

Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro
por: Xie, Bo, et al.
Publicado: (2018)

Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients
por: Ge, Wen-kai, et al.
Publicado: (2015)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
por: Lamond, Nathan WD, et al.
Publicado: (2014)

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
por: OSAKO, TOMOFUMI, et al.
Publicado: (2015)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
por: Larionov, Alexey A.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mqmjkb25p9m8tdgcjb0q36b5a4